Cargando…

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma

Epithelial ovarian cancer (EOC) is among the top five causes of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant cells to the peritoneum. Despite improvements in medical therapies, particularly with the implementation of novel drugs targeting homologou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Truxova, Iva, Cibula, David, Spisek, Radek, Fucikova, Jitka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950980/ https://www.ncbi.nlm.nih.gov/pubmed/36822672 http://dx.doi.org/10.1136/jitc-2022-005968

Ejemplares similares

Immunological configuration of ovarian carcinoma: features and impact on disease outcome
por: Fucikova, Jitka, et al.
Publicado: (2021)

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
por: Adkins, Irena, et al.
Publicado: (2015)

Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
por: Partlová, Simona, et al.
Publicado: (2015)

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy
por: MIKYŠKOVÁ, ROMANA, et al.
Publicado: (2015)

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients
por: Kasikova, Lenka, et al.
Publicado: (2019)

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients
por: Truxova, Iva, et al.
Publicado: (2018)

RNA-seq of macrophages of amoeboid or mesenchymal migratory phenotype due to specific structure of environment
por: Čermák, Vladimír, et al.
Publicado: (2018)

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
por: Hensler, Michal, et al.
Publicado: (2020)

Calreticulin arms NK cells against leukemia
por: Fucikova, Jitka, et al.
Publicado: (2019)

Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
por: Fucikova, Jitka, et al.
Publicado: (2019)

Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials
por: Fučíková, Jitka, et al.
Publicado: (2011)

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
por: Rakova, Jana, et al.
Publicado: (2021)

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
por: Rob, Lukas, et al.
Publicado: (2022)

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
por: Truxova, Iva, et al.
Publicado: (2020)

Trial watch: Peptide-based vaccines in anticancer therapy
por: Bezu, Lucillia, et al.
Publicado: (2018)

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
por: Holicek, Peter, et al.
Publicado: (2023)

Detection of immunogenic cell death and its relevance for cancer therapy
por: Fucikova, Jitka, et al.
Publicado: (2020)

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
por: Petty, Amy J., et al.
Publicado: (2021)

Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy
por: Zheng, Hongyu, et al.
Publicado: (2023)

Targeting tumor-associated macrophages to synergize tumor immunotherapy
por: Xiang, Xiaonan, et al.
Publicado: (2021)

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
por: Vanmeerbeek, Isaure, et al.
Publicado: (2020)

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer
por: Fucikova, Jitka, et al.
Publicado: (2015)

Immunotherapy Targeting Tumor-Associated Macrophages
por: Liu, Yafei, et al.
Publicado: (2020)

Corrigendum: “Combinatorial Strategies for the Induction of Immunogenic Cell Death”
por: Bezu, Lucillia, et al.
Publicado: (2015)

Combinatorial Strategies for the Induction of Immunogenic Cell Death
por: Bezu, Lucillia, et al.
Publicado: (2015)

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
por: Laureano, Raquel S, et al.
Publicado: (2022)

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy
por: Gupta, Vijayalaxmi, et al.
Publicado: (2018)

Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
por: Georgantzoglou, Natalia, et al.
Publicado: (2021)

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
por: Podrazil, Michal, et al.
Publicado: (2015)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
por: Xu, Shumin, et al.
Publicado: (2023)

Harnessing tumor-associated macrophages as aids for cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2019)

Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications
por: Zhu, Shunyao, et al.
Publicado: (2021)

Molecular imaging of tumor-associated macrophages in cancer immunotherapy
por: Li, Xiaoying, et al.
Publicado: (2022)

Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy
por: Schweer, David, et al.
Publicado: (2022)

Targeting macrophages in cancer immunotherapy
por: Duan, Zhaojun, et al.
Publicado: (2021)

Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines
por: Kloudová, Kamila, et al.
Publicado: (2016)

The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?
por: Mojsilovic, Sonja S., et al.
Publicado: (2021)

Tumor-associated macrophage-related strategies for glioma immunotherapy
por: Tang, Fansong, et al.
Publicado: (2023)

Metabolic Reprogramming in Tumor-Associated Macrophages in the Ovarian Tumor Microenvironment
por: Kumar, Sudhir, et al.
Publicado: (2022)

Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy
por: Khan, Safir Ullah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iug2j1036rc0cpirct3dean6oo